Compare Aurobindo Pharma with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs PFIZER - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA PFIZER AUROBINDO PHARMA/
PFIZER
 
P/E (TTM) x 10.5 39.1 26.9% View Chart
P/BV x 1.9 6.7 28.9% View Chart
Dividend Yield % 0.5 0.5 106.4%  

Financials

 AUROBINDO PHARMA   PFIZER
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
PFIZER
Mar-19
AUROBINDO PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs8303,840 21.6%   
Low Rs5272,080 25.3%   
Sales per share (Unadj.) Rs333.9455.0 73.4%  
Earnings per share (Unadj.) Rs40.493.8 43.0%  
Cash flow per share (Unadj.) Rs51.8109.4 47.3%  
Dividends per share (Unadj.) Rs2.5022.50 11.1%  
Dividend yield (eoy) %0.40.8 48.5%  
Book value per share (Unadj.) Rs237.1658.2 36.0%  
Shares outstanding (eoy) m585.9145.75 1,280.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.06.5 31.2%   
Avg P/E ratio x16.831.6 53.3%  
P/CF ratio (eoy) x13.127.1 48.4%  
Price / Book Value ratio x2.94.5 63.6%  
Dividend payout %6.224.0 25.8%   
Avg Mkt Cap Rs m397,569135,420 293.6%   
No. of employees `00017.92.6 678.6%   
Total wages/salary Rs m25,8493,238 798.2%   
Avg. sales/employee Rs Th10,956.97,911.4 138.5%   
Avg. wages/employee Rs Th1,447.71,230.9 117.6%   
Avg. net profit/employee Rs Th1,324.31,630.7 81.2%   
INCOME DATA
Net Sales Rs m195,63620,815 939.9%  
Other income Rs m1,5531,674 92.8%   
Total revenues Rs m197,18922,489 876.8%   
Gross profit Rs m39,5195,712 691.9%  
Depreciation Rs m6,680714 935.6%   
Interest Rs m2,62673 3,602.2%   
Profit before tax Rs m31,7676,599 481.4%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,2692,309 314.8%   
Profit after tax Rs m23,6454,291 551.1%  
Gross profit margin %20.227.4 73.6%  
Effective tax rate %22.935.0 65.4%   
Net profit margin %12.120.6 58.6%  
BALANCE SHEET DATA
Current assets Rs m153,64527,167 565.6%   
Current liabilities Rs m120,4298,917 1,350.6%   
Net working cap to sales %17.087.7 19.4%  
Current ratio x1.33.0 41.9%  
Inventory Days Days13568 199.4%  
Debtors Days Days6430 211.6%  
Net fixed assets Rs m103,9098,862 1,172.5%   
Share capital Rs m586458 128.1%   
"Free" reserves Rs m138,32229,656 466.4%   
Net worth Rs m138,90830,113 461.3%   
Long term debt Rs m1,80025 7,198.0%   
Total assets Rs m264,54439,400 671.4%  
Interest coverage x13.191.5 14.3%   
Debt to equity ratio x00 1,560.4%  
Sales to assets ratio x0.70.5 140.0%   
Return on assets %9.911.1 89.7%  
Return on equity %17.014.2 119.5%  
Return on capital %23.822.1 107.7%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,316428 22,721.6%   
Fx outflow Rs m40,589786 5,161.4%   
Net fx Rs m56,727-358 -15,841.2%   
CASH FLOW
From Operations Rs m16,220978 1,658.3%  
From Investments Rs m-28,768351 -8,191.4%  
From Financial Activity Rs m19,191-1,099 -1,747.0%  
Net Cashflow Rs m6,656231 2,884.1%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 8.0 7.5 106.0%  
FIIs % 27.7 4.9 565.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 23.7 43.0%  
Shareholders   69,601 85,207 81.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   J.B.CHEMICALS  ALEMBIC LTD  CIPLA  CADILA HEALTHCARE  SUVEN LIFESCIENCES  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 1,266 Points; Nifty Ends Above 9,100 Mark(Closing)

Indian share markets witnessed buying interest throughout the day and ended on a strong note.

Related Views on News

PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

A Safe Stock to Lockdown Now(The 5 Minute Wrapup)

Apr 2, 2020

The market crashc has made strong, established brands attractive. Here's a stock to make the most of this opportunity...

The Insiders See a Buying Opportunity in These Smallcaps Amid Coronavirus Outbreak(Profit Hunter)

Mar 31, 2020

The promoters are buying these smallcaps amid the coronavirus outbreak.

This Smallcap Tech Firm has Risen to the Coronavirus Challenge(Profit Hunter)

Apr 7, 2020

This smallcap tech firm is all set to emerge stronger from the Coronavirus crisis.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Apr 9, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS